‘Femtech’ is one of those newish umbrella terms that corrals health tech that enables women to manage their health better. Most of women’s health products cluster in birth control, fertility, pregnancy, and early maternity, with little outside this area or for older women. A number have gotten substantial funding rounds–in Q3, Nurx (birth control, $52M), The Pill Club ($51M, ditto), and Cleo (pregnancy and post-partum coaching, $27.5M). Rock Health
Research2Guidance has dug a little deeper in its new study,
The Global Market Of Digital Women’s Health Solutions 2017-2024 and discovered 3,000 app-based solutions, 151M annual downloads and millions of active users globally. 20 percent of US women in the femtech core demographic use a health app, and R2G projects global market revenue will reach $297 million. Global market expansion is likely to be greatest in countries like India and China
What femtech lacks, according to R2G’s Ralf Jahns, is validation. Those 3,000 companies haven’t quite concentrated on their user case and benefits which could lead to validation and payer/employer reimbursement. And strategies haven’t quite jelled yet.